Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1453194 | 0.85 | RAB9A (0.33) | KDM4EALDH1A1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL1453476 | 0.81 | LTA4H (0.33) | ALDH1A1RAB9ASMN1; SMN2LTA4HHTR1A | |
| SCHEMBL1452923 | 0.81 | LTA4H (0.33) | ALDH1A1RAB9ASMN1; SMN2LTA4HHTR1A | |
| SCHEMBL1452390 | 0.81 | RAB9A (0.34) | KDM4EALDH1A1RAB9ASMN1; SMN2LTA4H | |
| SCHEMBL1451739 | 0.80 | — | — | |
| SCHEMBL1451812 | 0.80 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL1453378 | 0.79 | LRRK2 (0.31) | — | |
| SCHEMBL1452697 | 0.78 | — | — | |
| SCHEMBL1453866 | 0.78 | KCNH2 (0.34) | KDM4EALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1453021 | 0.77 | CA12 (0.33) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-1971621-A1 | PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS | ExxonMobil Chemical Patents Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007070045-A1 | PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS | EXXONMOBIL CHEMICAL PATENTS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | KDM4E 3402/4885ALDH1A1 2182/4885RAB9A 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.